Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection.

BACKGROUND Neoadjuvant chemotherapy before resection of nonsmall cell lung cancer seems to increase survival, mainly in the early stage. Risks of postoperative complications after chemotherapy and surgery remain controversial. Here we review our experience with patients treated in one thoracic surgery center. METHODS Patients undergoing resection for nonsmall cell lung cancer after induction chemotherapy between January 1993 and March 2002 were reviewed. Data collected included age, sex, preoperative forced expiratory volume in 1 second (FEV1), hemoglobin, and arterial oxygen pressure tension (PaO2), postoperative complications, and global survival. The main objectives were postoperative mortality and morbidity. Postoperative mortality and morbidity were defined as complications or deaths occurring within 30 days after surgery. Predictive morbidity factors were identified by univariate and multivariate analysis and overall survival by the Kaplan-Meier method. RESULTS In all, 114 patients were reviewed. Different induction chemotherapies were used, mainly cisplatin with vinorelbine or gemicitabine. Postoperative mortality was 2 of 114, 1 of 27 after pneumonectomy, and there were no deaths after lobectomy. Complications occurred in 29% of patients (33 of 114), usually infectious pneumonia and anemia requiring transfusion. Preoperative FEV1, hemoglobin, and PaO2 are not associated with morbidity in univariate or multivariate analysis. CONCLUSIONS Preoperative chemotherapy does not increase postoperative mortality and morbidity after nonsmall cell lung cancer surgery, performed exclusively by thoracic surgeons.

[1]  D. Lackland,et al.  Specialists achieve better outcomes than generalists for lung cancer surgery. , 1998, Chest.

[2]  D. Cox.  Regression Models and Life-Tables , 1972 .

[3]  C. Begg,et al.  The influence of hospital volume on survival after resection for lung cancer. , 2001, The New England journal of medicine.

[4]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[5]  R. Ginsberg,et al.  Modern thirty-day operative mortality for surgical resections in lung cancer. , 1983, The Journal of thoracic and cardiovascular surgery.

[6]  J L Duque,et al.  Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía Torácica. , 1997, The Annals of thoracic surgery.

[7]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[8]  A. Bernard,et al.  Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. , 2001, The Journal of thoracic and cardiovascular surgery.

[9]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[10]  L. Beggs,et al.  Pneumonectomy for non-small cell lung cancer: predictors of operative mortality and survival. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  A. Mearns,et al.  Results of surgical treatment of stage I and II lung cancer. , 1996, The Journal of cardiovascular surgery.

[12]  H. Wada,et al.  Thirty-day operative mortality for thoracotomy in lung cancer. , 1998, The Journal of thoracic and cardiovascular surgery.

[13]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[14]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[15]  G. Myrdal,et al.  Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  R. Ginsberg,et al.  Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. , 1994, Chest.

[17]  M. Kris,et al.  Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. , 2001, The Annals of thoracic surgery.

[18]  S. Steinberg,et al.  Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. , 1992, The Annals of thoracic surgery.

[19]  J. Tschopp,et al.  Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung. , 2002, Chest.

[20]  N Cheynel,et al.  Identification of prognostic factors determining risk groups for lung resection. , 2000, The Annals of thoracic surgery.

[21]  Hak Choy,et al.  Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. , 2001, The Annals of thoracic surgery.

[22]  N. Estes,et al.  Perioperative Factors as Predictors of Operative Mortality and Morbidity in Pneumonectomy , 2001, The American surgeon.

[23]  E. Lemarié,et al.  Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.